Sirolimus is under clinical development by OrphAI Therapeutics and currently in Phase II for Bronchiolitis Obliterans.
Cantourage Group SE records strong growth in revenue and EBITDA in the break-even range in 2023. Strong growth since the partial legalisation of cannabis came into force. – Biotech Investments
EQS-News: Cantourage Group SE / Key word(s): Annual Results/Quarter Results Cantourage Group SE records strong growth in revenue and EBITDA in the break-even range in